Showing results (71-80 of 116) with videos related to

Sort By:
Pageof 12
AIDS (London, England)|November 4, 2000
Prevention of nevirapine-associated exanthema using slow dose escalation and/or corticosteroidsP Barreiro, V Soriano, E Casas, et al.
HIV Medicine|March 4, 2016
Relationship between plasma bilirubin level and oxidative stress markers in HIV-infected patients on atazanavir- vs. efavirenz-based antiretroviral therapyV Estrada, S Monge, M D Gómez-Garre, et al.
Revista De Investigacion Clinica; Organo Del Hospital De Enfermedades De La Nutricion|June 3, 1998
[Gastrointestinal hormones during minimal enteral feeding of sick premature infants]M R Ordaz-Jiménez, J M Fernández-Celis, S Rivera-Rosas, et al.
ACS Measurement Science Au|February 26, 2024
Abiotic, Hybrid, and Biological Electrocatalytic Materials Applied in Microfluidic Fuel Cells: A Comprehensive ReviewD V Estrada-Osorio, Ricardo A Escalona-Villalpando, M P Gurrola, et al.
Plos One|June 17, 2016
Refinement of Triple-Negative Breast Cancer Molecular Subtypes: Implications for Neoadjuvant Chemotherapy SelectionBrian D Lehmann, Bojana Jovanović, Xi Chen, et al.
HIV Clinical Trials|June 3, 2009
Long-term efficacy and safety of fosamprenavir plus ritonavir versus lopinavir/ritonavir in combination with abacavir/lamivudine over 144 weeksF Pulido, V Estrada, J G Baril, et al.
HIV Medicine|September 7, 2013
The CD4:CD8 ratio is associated with markers of age-associated disease in virally suppressed HIV-infected patients with immunological recoveryS Serrano-Villar, S Moreno, M Fuentes-Ferrer, et al.
HIV Medicine|February 20, 2007
Cervical lipomatosis in HIV-infected patients: a case-control studyR Palacios, M J Galindo, J A Arranz, et al.
HIV Medicine|September 15, 2005
A randomized controlled trial investigating the efficacy and safety of switching from a protease inhibitor to nevirapine in patients with undetectable viral loadJ A Arranz Caso, J C López, I Santos, et al.
HIV Medicine|January 10, 2013
Impact of switching from zidovudine/lamivudine to tenofovir/emtricitabine on lipoatrophy: the RECOMB studyE Ribera, M Larrousse, A Curran, et al.
Pageof 12